Innovation1 Biotech Inc.
IVBT
$0.0002
-$0.0048-96.00%
OTC PK
| 02/29/2024 | 11/30/2023 | 08/31/2023 | 05/31/2023 | 02/28/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -41.41% | -74.64% | -67.39% | -70.73% | -71.53% |
| Depreciation & Amortization | 0.00% | 0.00% | -99.96% | -99.97% | -99.97% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.36% | -75.22% | -88.30% | -87.24% | -85.62% |
| Operating Income | 41.36% | 75.22% | 88.30% | 87.24% | 85.62% |
| Income Before Tax | 51.99% | 59.60% | 88.04% | 81.43% | 66.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 51.99% | 59.60% | 88.04% | 81.43% | 66.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.99% | 59.60% | 88.04% | 81.43% | 66.08% |
| EBIT | 41.36% | 75.22% | 88.30% | 87.24% | 85.62% |
| EBITDA | 41.41% | 75.25% | 77.78% | 72.76% | 81.24% |
| EPS Basic | 94.21% | 43.77% | 90.70% | 71.49% | -331.87% |
| Normalized Basic EPS | 11.96% | 60.91% | 33.06% | 81.71% | 83.42% |
| EPS Diluted | 94.21% | 43.77% | 90.70% | 71.49% | -331.87% |
| Normalized Diluted EPS | 11.96% | 60.91% | 33.06% | 81.71% | 83.42% |
| Average Basic Shares Outstanding | 12.24% | 5.50% | 34.47% | 1.51% | 0.00% |
| Average Diluted Shares Outstanding | 12.24% | 5.50% | 34.47% | 1.51% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |